Zealand Pharma disappointing obesity topline results, Genmab completes large acquisition, KPHC up 2%

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week, the KPHC rose 2%, while the Danish healthcare stocks fell 2%. Genmab completed its acquisition of Profound Bio, Zealand Pharma presented disapointing topline results for an obesity drug, while Scandion Oncology fell 37% after they announced the terms of their rights issue.

9 of the 22 Danish healthcare companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 149% return and Circio Holding was the best Nordic healthcare investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.



Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List (Link)

Ascendis Pharma

No news the past week


No news the past week


No news the past week

CS Medica

No news the past week


Interim report Q1 2024 (Link)

DanCann Pharma

DanCann Pharma A/S: The Board of Directors has resolved on a partially (48.88 percent) secured Rights Issue of approximately DKK 18.33 million and publishes memorandum (Link)

Evaxion Biotech

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024 (Link)


No news the past week


No news the past week


Genmab Completes Acquisition of ProfoundBio (Link)


No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech to Present at Jefferies Global Healthcare Conference (Link)

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

Scandion Oncology announces the final terms of the rights issue (Link)

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech and healthcare stocks delivered a negative share price performance the past week of -2% compared to 2% for the KPHC index. Pila Pharma became the best performer without any news. Zealand Pharma fell slightly after the topline results for the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide seemed to disapoint a bit. Genmab completed the acquisition of ProfoundBio. Scandion Oncology fell 37% after they announced the terms of their rights issue.

The best stock year-to-date is Gubra followed by DanCann Pharma with 97-149% increases after the first 5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 4.6%.

Overview of share price developments the past week, year-to-date, and last twelve months


In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 2% to 63.89. The index has had a strong performance since the end of April and continues to recover from its all-time low in October of 57.12. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

81-268% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Circio Holding AB (268%) works with targeted immunotherapy used in the treatment of cancer patients. The company’s operations consist of research and development and the pharmaceuticals are currently sold under separate brands. Several partnerships in the market have been entered to strengthen cooperation in the development of new immunotherapy. 

XP Chemistries AB (113%) owns a patented technology for producing capsaicin from forest raw materials. Capsaicin is a fat-soluble, color- and odorless, waxy substance. Capsaicin is used today in most products, including animal feed, pest control, cosmetics, and medical products.

European Institute of Science AB (81%) main focus in on the development of diagnostic analyses used for clinical laboratory and point of care settings, primarily in veterinary health for dog, cat, and equine animals. The main business is found in the Nordic market.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.